News | September 03, 2008

Study Finds Defibrillator Shocks May Increase Mortality, HRS Disputes Claim

September 3, 2008 – Research published this week in the New England Journal of Medicine said patients with heart failure in whom an ICD is implanted and receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks.

The article “Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure,” centered on a multi-center study about long-term prognosis after ICD therapy in patients because research in this area is limited.

“Like many other studies, the SCD-HeFT trial clearly demonstrates that ICD devices save lives,” said Dr. N.A. Mark Estes, president of the Heart Rhythm Society, which defends the use of ICDs. “While there is an association between patients who are shocked and an increased mortality, receiving a life-saving shock does not independently predict a patient’s survival rate.”

The HRS issued a release following publication of the article noting that while the study shows a link between ICD shocks and patient mortality, patients who received shocks were in worse health prior to the shock than those who were not shocked. The increased mortality rate is related to their overall health condition rather than ICD activity. Patients receive shocks to stop potentially life-threatening heart rhythms, and many recent studies have shown a drastic decrease in the number of inappropriate shocks. The HRS said.

The study followed 811 patients with heart failure who receive an implantable cardioverter–defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) and may have later receive therapeutic shocks from the ICD. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate, and all other ICD shocks were considered to be inappropriate for the purpose of the study.

The during the median follow-up period of 45.5 months, 269 patients (33.2 percent) received at least one ICD shock. Of those, 87 were considered inappropriate and 54 patients receiving both appropriate and inappropriate shocks.

In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes. Researchers also found an inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death. For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated. The most common cause of death among patients who received any ICD shock was progressive heart failure.

Researchers were from University of Washington; the Seattle Institute for Cardiac Research; Duke Clinical Research Institute; Durham, NC; University of Pennsylvania, Philadelphia; Portland Veterans Affairs Medical Center and Oregon Health Sciences University, Portland; Oregon Cardiology Associates, Eugene; University Hospital, London, ON, Canada; Johns Hopkins University, Baltimore; Institut de Cardiologie de Montréal, Université de Montréal, Montreal; Loyola University Medical Center, Maywood, IL; and the Mayo Clinic, Rochester, MN.

The Heart Rhythm Society reiterated its stance on the importance of ICDs in patients with life-threatening arrhythmias, and said ICDs are 99 percent effective in stopping life-threatening arrhythmias. The HRS said ICDs are the most successful therapy to treat ventricular fibrillation, the major cause of sudden cardiac arrest. However, only 35 percent of patients who could be helped by an ICD have one. ICDs continuously monitor the heart rhythm, automatically function as pacemakers for heart rates that are too slow, and deliver life-saving shocks if a dangerously fast heart rhythm is detected.

For more information: www.nejm.org, www.hrsonline.org


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 18, 2022 — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients ...

Home August 18, 2022
Home
Subscribe Now